Third Rock Ventures

Third Rock Ventures is a venture capital firm based in Boston and San Francisco, specializing in the life sciences sector. Since its founding in 2007, Third Rock has focused on investing in transformative biotech companies with the potential to make significant impacts on patients' lives. The firm has raised over $3.4 billion across multiple funds, with its most recent fund closing at $1.1 billion in June 2022. Notable investments include bluebird bio, Editas Medicine, and Relay Therapeutics. Third Rock is known for its hands-on approach, often playing a leading role in the formation and early development of its portfolio companies. They invest heavily in early-stage projects, supporting them through significant milestones with substantial capital injections. Third Rock Ventures has built a robust portfolio with companies such as Marea Therapeutics, Seaport Therapeutics, and Synnovation Therapeutics. Their strategic focus areas include gene therapy, immuno-oncology, precision medicine, and neuropsychiatry.